Effect of low frequency electro-acupuncture (EA) on polycystic ovary syndrome: study protocol of a double-blind, sham-controlled, randomized trial

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-12002529

Enrollment

Unknown

Registered

2012-09-04

Start date

2012-10-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

polycystic ovary syndrome

Interventions

control group:lsham acupuncture

treatment group:low frequency electro-acupuncture

Eligibility

Sex/Gender

Female

Age

18 Years to 28 Years

Inclusion criteria

Inclusion criteria: 1) female, 18-28 years old, unmarried, no fertility requirements;2) according to Rotterdam diagnostic criteria of polycystic ovary syndrome: All patients must meet the following requirements:scarce menstruation (menstrual cycle > 35 days or less than 8 menstrual cycle each year,) or amenorrhea (the interval > 90 days between 2 times of menstruation), and one of the following two standards: clinical or biochemical hyperandrogenemia and polycystic ovary.

Exclusion criteria

Exclusion criteria: 1) hyperprolactinemia patients; 2) patients with abnormal increased androgen secretion because of adrenal or ovarian tumor; 3) Patients with thyroid disease (defined as TSH 5.5 mIU/mL). In the past one year, patients with normal TSH level can be recruited into the group; 4) Patients with Suspected Cushing syndrome; 5)patients who used estrogen, progesterone or oral contraceptives and hormone drugs in the last one month, which need 1 month of drug clearance in order to avoid the interference with the experiment; 4) patients who used other drugs which could affect reproductive or metabolic function (such as anti-obesity drugs, diabetes-resisting drugs and traditional Chinese medicine, etc.) in the last 2 months; 5) patients who received acupuncture treatment in the last three months; 6) patients who decline to sign the informed consent.

Design outcomes

Primary

Measure	Time frame
a change in HCG-induced hyperandrogenism including 17-a-hydroxyprogesterone (17-OHP) , androstenedione (A2) and testosterone.;	—

Secondary

Measure	Time frame
serum FSH;serum LH;serum testerone;fast blood glucose;fast insulin;fast resistin;blood lipid level;serum adiponectin;mentrual frequency;	—

Countries

China

Contacts

Public ContactDongmei Huang, Xiaoke Wu

hdmjcr@qq.com+86 15327130928; +8613796025599

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 22, 2026